{"id":68385,"date":"2026-06-17T15:15:30","date_gmt":"2026-06-17T07:15:30","guid":{"rendered":"https:\/\/flcube.com\/?p=68385"},"modified":"2026-06-17T15:15:31","modified_gmt":"2026-06-17T07:15:31","slug":"shanghai-juncell-therapeutics-files-for-hkex-listing-with-breakthrough-til-therapy-gc101-for-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68385","title":{"rendered":"Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors"},"content":{"rendered":"\n

Shanghai Juncell Therapeutics Co., Ltd.<\/strong> announced it has published its prospectus<\/strong> and filed for listing<\/strong> on the Hong Kong Stock Exchange (HKEX)<\/strong>. The company is advancing GC101<\/strong>, the world’s first tumor-infiltrating lymphocyte (TIL) therapy that eliminates the need for high-intensity lymphodepleting chemotherapy or IL-2 administration, for the treatment of solid tumors including advanced melanoma and non-small cell lung cancer (NSCLC).<\/p>\n\n\n\n

Corporate Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Shanghai Juncell Therapeutics Co., Ltd.<\/td><\/tr>
Founded<\/strong><\/td>2019<\/td><\/tr>
Headquarters<\/strong><\/td>Shanghai, China<\/td><\/tr>
Listing Venue<\/strong><\/td>Hong Kong Stock Exchange (HKEX)<\/td><\/tr>
Filing Status<\/strong><\/td>Prospectus published, listing application submitted<\/td><\/tr>
Core Focus<\/strong><\/td>Research, development, and commercialization of cell therapies for solid tumors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n